Status:
COMPLETED
Airway Inflammation, Symptoms and Lung Function in COPD
Lead Sponsor:
Università degli Studi di Ferrara
Collaborating Sponsors:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40-75 years
Brief Summary
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease with high prevalence worldwide and with relevant impact on patient-related quality of life, morbidity and mortality. Ther...
Detailed Description
Patients will undergo a visit every 7 days during one month (5 visits in total). At each visit airway inflammation (exhaled NO, sputum inflammatory cell count) and lung function will be performed. At ...
Eligibility Criteria
Inclusion
- Post-bronchodilator FEV1/FVC ratio \< 70%
- Post-bronchodilator FEV1 \< 80%
- Smokers or ex-smoker with pack/years \> 15
Exclusion
- Atopy
- Asthma
- Concomitant lung diseases (e.g. lung cancer)
- Acute infections of the respiratory tree in the previous 2 months including COPD exacerbation.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01216592
Start Date
January 1 2009
End Date
July 1 2011
Last Update
December 6 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Centre on Asthma and COPD - Department of Clinical and Experimental Medicine - Section of Respiratory Disease - University of Ferrara
Ferrara, Italy, 44121